CLS 12311
Alternative Names: Autologous Peptide-coupled Red Blood Cells - Cellerys; CLS-12311Latest Information Update: 27 Jun 2024
At a glance
- Originator Cellerys
- Developer Cellerys; Novartis
- Class Cell therapies; Peptides
- Mechanism of Action Blood cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple sclerosis
Most Recent Events
- 18 Jun 2024 Phase-I/II clinical trials in Multiple sclerosis in Switzerland (IV) (NCT06430671)
- 03 Aug 2023 Phase-I clinical trials in Multiple sclerosis in Switzerland (IV), before July 2023 (Cellerys pipeline, July 2023)
- 03 Aug 2023 Cellerys completes phase I trial in Multiple sclerosis in Switzerland (IV), prior to July 2023 (Cellerys pipeline, July 2023)